Skip to main content
Erschienen in: Herz 1/2020

17.06.2019 | Original articles

Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome

verfasst von: Prof. H. M. Nef, MD, J. Wiebe, MD, G. Schmidt, H. Möllmann, MD, N. F. Boeder, MD, O. Dörr, MD, T. Bauer, MD, F. Blachutzik, MD, C. Liebetrau, MD, A. Elsässer, MD, N. Foin, MSc, PhD, C. W. Hamm, MD

Erschienen in: Herz | Sonderheft 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Limited data exist on bioresorbable scaffolds (BRS) in patients with acute coronary syndrome (ACS). The aim of the present study was to evaluate novolimus-eluting BRS (DESolve) as interventional treatment for patients with ACS, and to compare its 12-month outcomes with the everolimus-eluting bioresorbable scaffolds (Absorb).

Methods

In this retrospective study, patients with ACS (including unstable angina pectoris, ST-segment elevation myocardial infarction, or non-ST-segment elevation myocardial infarction) treated with either the Absorb or the DESolve BRS were evaluated in a 1:1 matched-pair analysis. Major adverse cardiac events (MACE), including death, myocardial infarction, and target lesion revascularization, were evaluated as a major endpoint. The occurrence of scaffold thrombosis was also assessed.

Results

A total of 102 patients were eligible for this analysis. The rate of MACE at 12 months was comparable between the Absorb and the DESolve group (8.3% vs. 6.8%, p = 0.738). The occurrence of target lesion revascularization (6.2% vs. 4.7%; p = 0.700) and scaffold thrombosis (4.1% vs. 2.1%; p = 0.580) was comparable as well. All instances of scaffold thrombosis occurred within 30 days of the index procedure.

Conclusion

In this study, similar 12-month event rates were observed for both BRS types after implantation for the treatment of ACS.
Literatur
7.
Zurück zum Zitat Byrne RA, Alfonso F, Schneider S et al (2019) Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. Eur Heart J 40(2):167–176. https://doi.org/10.1093/eurheartj/ehy710CrossRefPubMed Byrne RA, Alfonso F, Schneider S et al (2019) Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. Eur Heart J 40(2):167–176. https://​doi.​org/​10.​1093/​eurheartj/​ehy710CrossRefPubMed
10.
Zurück zum Zitat Bourantas CV, Serruys PW, Nakatani S et al (2015) Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data. EuroIntervention 11(7):746–756. https://doi.org/10.4244/EIJY14M10_06CrossRefPubMed Bourantas CV, Serruys PW, Nakatani S et al (2015) Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data. EuroIntervention 11(7):746–756. https://​doi.​org/​10.​4244/​EIJY14M10_​06CrossRefPubMed
13.
Zurück zum Zitat Dudek D (2014) Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study. Pol Arch Med Wewn 124(12):669–677PubMed Dudek D (2014) Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study. Pol Arch Med Wewn 124(12):669–677PubMed
15.
Zurück zum Zitat Karanasos A, Muramatsu T, Diletti R et al (2015) Early and late optical coherence tomography findings following everolimus-eluting bioresorbable vascular scaffold implantation in myocardial infarction: a preliminary report. Hellenic J Cardiol 56(2):125–135PubMed Karanasos A, Muramatsu T, Diletti R et al (2015) Early and late optical coherence tomography findings following everolimus-eluting bioresorbable vascular scaffold implantation in myocardial infarction: a preliminary report. Hellenic J Cardiol 56(2):125–135PubMed
16.
17.
23.
Zurück zum Zitat Fam JM, Felix C, van Geuns RJ et al (2016) Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study. EuroIntervention 12(1):30–37. https://doi.org/10.4244/EIJV12I1A6CrossRefPubMed Fam JM, Felix C, van Geuns RJ et al (2016) Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study. EuroIntervention 12(1):30–37. https://​doi.​org/​10.​4244/​EIJV12I1A6CrossRefPubMed
26.
Zurück zum Zitat Brugaletta S, Gori T, Low AF et al (2015) Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1‑year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv 8(1 Pt B):189–197. https://doi.org/10.1016/j.jcin.2014.10.005CrossRefPubMed Brugaletta S, Gori T, Low AF et al (2015) Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1‑year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv 8(1 Pt B):189–197. https://​doi.​org/​10.​1016/​j.​jcin.​2014.​10.​005CrossRefPubMed
27.
Zurück zum Zitat Sabate M, Windecker S, Iniguez A et al (2016) Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J 37(3):229–240. https://doi.org/10.1093/eurheartj/ehv500CrossRefPubMed Sabate M, Windecker S, Iniguez A et al (2016) Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J 37(3):229–240. https://​doi.​org/​10.​1093/​eurheartj/​ehv500CrossRefPubMed
Metadaten
Titel
Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome
verfasst von
Prof. H. M. Nef, MD
J. Wiebe, MD
G. Schmidt
H. Möllmann, MD
N. F. Boeder, MD
O. Dörr, MD
T. Bauer, MD
F. Blachutzik, MD
C. Liebetrau, MD
A. Elsässer, MD
N. Foin, MSc, PhD
C. W. Hamm, MD
Publikationsdatum
17.06.2019
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe Sonderheft 1/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-019-4822-7

Weitere Artikel der Sonderheft 1/2020

Herz 1/2020 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.